<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="360">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 24, 2013</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01386710</url>
  </required_header>
  <id_info>
    <org_study_id>1012011410</org_study_id>
    <nct_id>NCT01386710</nct_id>
  </id_info>
  <brief_title>Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma</brief_title>
  <official_title>Phase I/II Trial Of Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory Glioblastoma Multiforme And Anaplastic Astrocytoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The high-grade malignant brain tumors, glioblastoma multiforme (GBM) and anaplastic
      astrocytoma (AA), comprise the majority of all primary brain tumors in adults.  This group
      of tumors also exhibits the most aggressive behavior, resulting in median overall survival
      durations of only 9-12 months for GBM, and 3-4 years for AA. Initial therapy consists of
      either surgical resection, external beam radiation or both.  All patients experience a
      recurrence after first-line therapy, so improvements in both first-line and salvage therapy
      are critical to enhancing quality-of-life and prolonging survival.  It is unknown if
      currently used intravenous (IV) therapies even cross the blood brain barrier (BBB). The
      investigators have shown in a previous phase I trial that a single Superselective
      Intraarterial Cerebral Infusion (SIACI) of Bevacizumab (up to 15mg/kg) is safe and effective
      in the treatment of recurrent GBM.  Therefore, this phase I/II clinical research trial is an
      extension of that trial in that the investigators seek to test the hypothesis that repeated
      dosing of intra-arterial Bevacizumab is safe and effective in the treatment of recurrent
      malignant glioma. Additionally the investigators will analyze if a combination with IA
      Carboplatin will further improve the treatment response. By achieving the aims of this study
      the investigators will also determine if IV therapy with Bevacizumab with IV Carboplatin
      should be combined with repeated selected intra-arterial Bevacizumab plus Carboplatin to
      improve progression free and overall survival. The investigators expect that this project
      will provide important information regarding the utility of repeated SIACI Bevacizumab
      therapy for malignant glioma, and may alter the way these drugs are delivered to the
      investigators patients in the near future.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2011</start_date>
  <primary_completion_date type="Anticipated">January 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Composite overall response rate</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The composite overall response rate (CORR) will be examined. The overall response proportion along with a 95% confidence interval will be estimated via binomial proportions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Six-month progression-free survival (PFS) and overall survival (OS)</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>PFS will be measured from the date of the first dose of SIACI Bevacizumab plus Carboplatin to the date of progression.  OS will be measured from the date of the first dose of SIACI Bevacizumab plus Carboplatin to the date of death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The safety of repeated SIACI of Mannitol, Bevacizumab plus Carboplatin at 15mg/kg and 150mg/m2 respectively.</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The descriptive frequency of subjects experiencing toxicities will also be tabulated.  Toxicities will be assessed and graded according to the NCI Common Toxicity Criteria, version 3.0.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <condition>Anaplastic Astrocytoma</condition>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Bevacizumab and Carboplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Bevacizumab and Carboplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab and Carboplatin</intervention_name>
    <description>Day 0:  Intraarterial Bevacizumab single dose (15mg/kg) plus Intraarterial Carboplatin (150mg/m2) after Mannitol to open the blood brain barrier
Day 28: Intravenous Bevacizumab (10mg/kg) plus Carboplatin (AUG5) every two weeks thereafter until disease progression on MRI scan.
If progression occurs, repeat intraarterial Bevacizumab single dose (15mg/kg) plus intraarterial Carboplatin (150mg/m2) to area of progression and wait 28 days and then restart Intravenous Bevacizumab (10mg/kg) plus Carboplatin (AUG5) every two weeks thereafter until progression on MRI scan.
Repeat Cycle</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab and Carboplatin</intervention_name>
    <description>Day 0:  Intraarterial Bevacizumab single dose (15mg/kg) plus Intraarterial Carboplatin (150mg/m2) after Mannitol to open the blood brain barrier
Day 28: No biweekly IV Bevacizumab plus Carboplatin treatment
If MRI shows progression then repeat intraarterial Bevacizumab single dose (15mg/kg) plus intraarterial Carboplatin (150mg/m2) to area of progression Repeat Cycle</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older.

          -  Documented histologic diagnosis of relapsed or refractory glioblastoma multiforme
             (GBM), anaplastic astrocytoma (AA) or anaplastic mixed oligoastrocytoma (AOA).

          -  Circumscribed tumor recurrence with less than 3.5 cm greatest diameter

          -  Patients with histologically confirmed low-grade brain tumor relapse with an
             enhancing tumor on MRI will be evaluated for toxicity only.

          -  Patients must have at least one confirmed and evaluable tumor site.

          -  Patients must have a Karnofsky performance status 70% (or the equivalent ECOG level
             of 0-2)

          -  Patients must agree to use a medically effective method of contraception during and
             for a period of three months after the treatment period.

        Exclusion Criteria:

          -  Women who are pregnant or lactating.

          -  Patients with significant intercurrent medical or psychiatric conditions that would
             place them at increased risk or affect their ability to receive or comply with
             treatment or post-treatment clinical monitoring.

          -  Low GFR or history of hepatorenal syndrome
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Boockvar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John Boockvar, MD</last_name>
    <phone>212-746-1996</phone>
    <email>Jab2029@med.cornell.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tamika Wong</last_name>
    <phone>212-746-1788</phone>
    <email>taw2015@med.cornell.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Susan Pannullo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ehud Lavi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Tsiouris, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zuzan Cayci, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sherese Fralin, NP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Zimmerman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://druginfo.nlm.nih.gov/drugportal/ProxyServlet?mergeData=true&amp;objectHandle=DBMaint&amp;APPLICATION_NAME=drugportal&amp;actionHandle=default&amp;nextPage=jsp/drugportal/ResultScreen.jsp&amp;TXTSUPERLISTID=0216974753&amp;QV1=BEVACIZUMAB</url>
    <description>Drug Information available for: Bevacizumab</description>
  </link>
  <link>
    <url>http://druginfo.nlm.nih.gov/drugportal/ProxyServlet?mergeData=true&amp;objectHandle=DBMaint&amp;APPLICATION_NAME=drugportal&amp;actionHandle=default&amp;nextPage=jsp/drugportal/ResultScreen.jsp&amp;TXTSUPERLISTID=0041575944&amp;QV1=CARBOPLATIN</url>
    <description>Drug information for: Carboplatin</description>
  </link>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 18, 2012</lastchanged_date>
  <firstreceived_date>June 13, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Weill Medical College of Cornell University</investigator_affiliation>
    <investigator_full_name>John A. Boockvar</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>GBM</keyword>
  <keyword>AA</keyword>
  <keyword>AO</keyword>
  <keyword>Brain</keyword>
  <keyword>Tumors</keyword>
  <keyword>Malignant</keyword>
  <keyword>Glioblastoma</keyword>
  <keyword>Multiforme</keyword>
  <keyword>Anaplastic</keyword>
  <keyword>Astrocytoma</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
